iab22m2c
mAbexperimentalImaging agent
Clinical trial activity
12 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2018 (NCT03802123)
Timeline
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 1
- Leukoencephalopathy, Progressive Multifocal · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1
- Melanoma · Phase 2
- Multiple Sclerosis · Phase 1
- Neoplasms · Phase 2
- Positron-Emission Tomography · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
CD8A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314651 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06863233 | Phase 1 | Mar 3, 2025 | Memorial Sloan-Kettering Cancer Center |
| NCT06534190 | Phase 2 | Aug 31, 2024 | University of Groningen |
| NCT06457789 | N/A | Jul 31, 2024 | Free University of Amsterdam, National Institutes of Health (NIH) |
| NCT05849467 | Phase 1 | Oct 19, 2023 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT05744128 | Phase 2 | Feb 16, 2023 | ImaginAb, Inc., University of Hull |
| NCT05371132 | Phase 1 | Jun 20, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05397171 | Phase 1/Phase 2 (Phase 2) | Jun 7, 2022 | AstraZeneca, ImaginAb, Inc. |
| NCT05279027 | Early Phase 1 (Phase 1) | Mar 8, 2022 | ImaginAb, Inc., University of Pennsylvania |
| NCT04826393 | Phase 1 | Dec 31, 2021 | Astellas, Harvard University, ImaginAb, Inc., Regeneron |
| NCT05013099 | Phase 2 | Sep 30, 2021 | City of Hope National Medical Center, ImaginAb, Inc. |
| NCT04955262 | Phase 1 | Aug 31, 2019 | ImaginAb, Inc., Nektar Therapeutics |
| NCT03802123 | Phase 2 | Dec 18, 2018 | ImaginAb, Inc. |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImaginAb, Inc. | For profit | 7 | 3 | 2 | 2018 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 1 | 2 | 2021 |
| Astellas | For profit | 1 | 0 | 1 | 2021 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2022 |
| Free University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2023 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| Nektar Therapeutics | For profit | 1 | 1 | 1 | 2019 |
| Regeneron | For profit | 1 | 0 | 1 | 2021 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Hull | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2022 |
15 organizations
Page 1 / 1